NASDAQ:GTHX - G1 Therapeutics Stock Price, Forecast & News

G1 Therapeutics trades on the NASDAQ under the ticker symbol "GTHX."

G1 Therapeutics Inc (NASDAQ:GTHX) posted its earnings results on Tuesday, November, 5th. The company reported ($0.86) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.87) by $0.01. View G1 Therapeutics' Earnings History.

G1 Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for G1 Therapeutics.

7 Wall Street analysts have issued twelve-month price targets for G1 Therapeutics' shares. Their forecasts range from $45.00 to $82.00. On average, they expect G1 Therapeutics' stock price to reach $67.17 in the next year. This suggests a possible upside of 202.6% from the stock's current price. View Analyst Price Targets for G1 Therapeutics.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for G1 Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for G1 Therapeutics.

Media headlines about GTHX stock have trended somewhat negative on Monday, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. G1 Therapeutics earned a news impact score of -1.4 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for G1 Therapeutics.

G1 Therapeutics saw a decrease in short interest in January. As of January 15th, there was short interest totalling 4,080,000 shares, a decrease of 13.7% from the December 31st total of 4,730,000 shares. Based on an average daily volume of 324,600 shares, the days-to-cover ratio is currently 12.6 days. Currently, 13.5% of the company's shares are short sold. View G1 Therapeutics' Current Options Chain.

Some companies that are related to G1 Therapeutics include Ultragenyx Pharmaceutical (RARE), Blueprint Medicines (BPMC), Taro Pharmaceutical Industries (TARO), Myokardia (MYOK), Zai Lab (ZLAB), Intercept Pharmaceuticals (ICPT), PTC Therapeutics (PTCT), HUTCHISON CHINA/S (HCM), Agios Pharmaceuticals (AGIO), Apellis Pharmaceuticals (APLS), Axsome Therapeutics (AXSM), Genmab A/S (GMAB), Emergent Biosolutions (EBS), Biohaven Pharmaceutical (BHVN) and Alkermes (ALKS).

Based on aggregate information from My MarketBeat watchlists, some companies that other G1 Therapeutics investors own include Rite Aid (RAD), OASMIA PHARMACE/ADR (OASM), Sorrento Therapeutics (SRNE), Alibaba Group (BABA), Exelixis (EXEL), Viking Therapeutics (VKTX), Bellicum Pharmaceuticals (BLCM), Corbus Pharmaceuticals (CRBP), Eyepoint Pharmaceuticals (EYPT) and Fate Therapeutics (FATE).

(GTHX) raised $101 million in an initial public offering (IPO) on Wednesday, May 17th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Cowen and Company acted as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.

G1 Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Rhenman & Partners Asset Management AB (0.70%), California Public Employees Retirement System (0.21%) and Alpine Global Management LLC (0.04%). Company insiders that own G1 Therapeutics stock include Barclay A Phillips, Clay Thorp, Cynthia Schwalm, James S Hanson, Jay Strum, Jennifer K Moses, John Demaree, Mark A Velleca, Rajesh Malik, Seth Rudnick and Terry L Murdock. View Institutional Ownership Trends for G1 Therapeutics.

GTHX stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB. View Insider Buying and Selling for G1 Therapeutics.

GTHX stock was bought by a variety of institutional investors in the last quarter, including Alpine Global Management LLC and California Public Employees Retirement System. Company insiders that have bought G1 Therapeutics stock in the last two years include Cynthia Schwalm, James S Hanson and John Demaree. View Insider Buying and Selling for G1 Therapeutics.

Shares of GTHX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of GTHX stock can currently be purchased for approximately $22.20.

G1 Therapeutics has a market capitalization of $834.32 million. The company earns $-85,290,000.00 in net income (profit) each year or ($2.56) on an earnings per share basis. G1 Therapeutics employs 84 workers across the globe.View Additional Information About G1 Therapeutics.

The official website for G1 Therapeutics is http://www.g1therapeutics.com/.

G1 Therapeutics' mailing address is 700 Park Offices Drive Suite 200, Research Triangle Park NC, 27709. The company can be reached via phone at 919-213-9835 or via email at [email protected]